Related Experiment Video
Updated: Jul 7, 2026
08:31
Characterization of Human Monocyte-derived Dendritic Cells by Imaging Flow Cytometry: A Comparison between Two Monocyte Isolation Protocols
Published on: October 18, 2016
Characterization of monocyte-derived IFNalpha-generated dendritic cells.
B Jacobs1, M Wuttke, C Papewalis
1Department of Endocrinology, Diabetes, and Rheumatology, University Hospital Duesseldorf, Duesseldorf, Germany.
Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones Et Metabolisme
|February 20, 2008
Summary
Interferon-alpha (IFN-alpha) generates unique dendritic cells (IFN-DCs) that express CD56 and possess direct anti-tumor immunity. These CD56+ IFN-DCs show enhanced T-cell stimulation and phagocytosis, indicating potential for cancer therapy.
Area of Science:
- Immunology
- Cell Biology
- Cancer Research
Background:
- Interferon-alpha (IFN-alpha) mediates anti-tumor effects through immune cell activation.
- Dendritic cells (DCs) are potent antigen-presenting cells crucial for anti-tumor immunity.
- Previously identified IFN-alpha-induced DCs (IFN-DCs) express CD56 and exhibit cytotoxic activity.
Purpose of the Study:
- To investigate the phenotypical and functional characteristics of CD56-expressing IFN-alpha-induced dendritic cells (IFN-DCs).
- To compare CD56+ IFN-DCs with CD56- IFN-DCs to understand their relationship and potential roles in anti-cancer immunity.
Main Methods:
- Flow cytometry was used to analyze CD56 and CD14 expression on monocytes cultured with IFN-alpha over five days.
- Negatively selected CD56- IFN-DCs were cultured to assess CD56 expression.
- Functional assays evaluated phagocytosis capacity and T-cell stimulation potential of CD56+ and CD56- IFN-DCs.
Main Results:
- CD14+ monocytes cultured with IFN-alpha showed a significant increase in CD56 surface expression over five days.
- CD56+ IFN-DCs exhibited decreased CD14 expression compared to CD56- IFN-DCs.
- CD56+ IFN-DCs demonstrated enhanced phagocytosis and superior T-cell stimulation capacity compared to CD56- IFN-DCs.
Conclusions:
- CD56+ IFN-DCs and CD56- IFN-DCs likely represent different maturation stages of the same cell population, not distinct entities.
- These CD56+ IFN-DCs possess direct cytolytic effects and potent immune-stimulating properties.
- CD56+ IFN-DCs represent a promising cellular tool for developing novel anti-cancer therapies.
